Japan Exchange
03:30:00 18/07/2024 BST
5-day change
1st Jan Change
205
JPY
+3.54%
+10.22%
+7.89%
AccuRna, Inc. announced that it has received ¥520 million in funding from Fast Track Initiative, Inc., UTokyo Innovation Platform Co., Ltd., NanoCarrier Co., Ltd., SMBC Venture Capital Co., Ltd.
AccuRna, Inc announced that it has raised gross proceeds of ¥520,000,000 on January 17, 2018. The transaction included participation from Fast Track Initiative, Inc, UTokyo Innovation Platform Co., Ltd, SMBC Venture Capital Co., Ltd and NanoCarrier Co., Ltd. (TSE:4571).
NANO MRNA, Kao Tie Up to Develop mRNA Therapies for Allergic Diseases
11-15
MT
NANO MRNA Co., Ltd. and Kao Corporation Agree a Comprehensive Collaborative Research for mRNA Drug Discovery
11-14
CI
NanoCarrier Co., Ltd. announced that it has received ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.
11/06/23
CI
NanoCarrier Co., Ltd. announced that it expects to receive ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.
25/05/23
CI
NanoCarrier Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
12/05/23
CI
US Patent Office Grants Patrys Two New Deoxymab Patents
18/04/23
MT
NanoCarrier Co., Ltd. announced that it has received ¥1.11096909 billion in funding from Whiz Partners Inc.
12/02/23
CI
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.11096909 billion in funding from Whiz Partners Inc.
24/01/23
CI
NanoCarrier Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2022
11/11/22
CI
NanoCarrier Co., Ltd. Commences in Domestic Patients Administration of VB-111, A Gene Therapy Product Global Phase III Trial in Platinum-Resistant Ovarian Cancer
10/06/21
CI
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.15292206 billion in funding from THE KENKO FUTURE Limited Partnership
22/04/21
CI
Nanocarrier : Concludes NC-6004 Phase III Clinical Study for Pancreatic Cancer
30/11/20
MT
NanoCarrier Announces the Conclusion of NC-6004 Phase III Clinical Study for Pancreatic Cancer
27/11/20
CI
Nanocarrier : Administers Head and Neck Cancer Drug NC-6004 to First Patient
06/11/20
MT
Nanocarrier Co., Ltd. Starts Administering NC-6004 in the Phase IIb Clinical Study in Combination with Keytruda for Head and Neck Cancer
05/11/20
CI
NanoCarrier Presents Favorable Data from Phase IIa Portion of NC-6004 Phase II Clinical Study in Combination with Keytruda
26/10/20
CI
NanoCarrier Co., Ltd. completed the acquisition remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka.
29/09/20
CI
NanoCarrier Co., Ltd. Announces the First Participant Dosed in Investigator-Initiated Phase I Clinical Trial in Patients with Breast Cancer in Japan
02/09/20
CI
NanoCarrier Co., Ltd. signed an agreement to acquire remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka for ¥1.7 billion.
14/07/20
CI
NanoCarrier Co., Ltd. Achieves Primary Endpoint in Phase IIa portion of NC-6004 Phase II Clinical Study in Combination with Keytruda for Head and Neck Cancer
17/06/20
CI
VBL Therapeutics Announces Nanocarrier Co., Ltd., Intends to Extend the Ongoing Global Phase 3 Oval Clinical Trial in Ovarian Cancer to Patients in Japan
02/04/20
CI
NanoCarrier Co., Ltd. Announces Earnings Results for the Nine Months Ended December 31, 2019; Provides Earnings Guidance for the Year Ending March 31, 2020
13/02/20
CI
NanoCarrier Co., Ltd. Reports Non-Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Earnings Guidance for the Year Ending March 31, 2020
13/11/19
CI
Nanocarrier Announces Development of NC-6300 Reaches a New Phase in the U.S. and Commences Administration to Participating Patients
02/10/19
CI
NanoCarrier Co., Ltd. Announces Non-Consolidated Earnings Results for the First Quarter Ended June 30, 2019; Provides Earnings Guidance for the Full Year Ending March 31, 2020
08/08/19
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Nano Mrna Co Ltd, formerly NanoCarrier Co Ltd, is mainly engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company develops businesses using the research and development of messenger ribonucleic acid (mRNA) medicine. The products under development are specialized in mRNA medicines. mRNA medicine is a medicine that prevents or treats diseases by administering artificially produced mRNA to the body and allowing the body to discover the protein encoded by the mRNA. Its pipeline includes RUNX1, the mRNA drug pipeline, non-mRNA drug pipeline, Comrex otological liquid 1.5%, NC-6100, TUG1, and others.
More about the company
1st Jan change
Capi.
+7.89% 84.77M +20.03% 126B +23.61% 118B +23.26% 27.87B -18.07% 20.95B -15.13% 16.92B -14.81% 16.18B +9.78% 14.84B -46.10% 14.79B +52.34% 14.08B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
NANO MRNA CO.,LTD. 